Yersinia outer protein m (yopm) in the treatment of psoriasis

Abstract

The present invention relates to the use of Yersinia outer protein M (YopM) in the prevention and/or treatment of psoriasis by cutaneous, intradermal or subcutaneous administration. In particular, the present invention relates to the use of YopM in the treatment of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, arthritis psoriasis.

What is claimed is: 
     
         1 . A method for the prevention of psoriasis in a human subject, comprising a step of administering a pharmaceutical composition comprising  Yersinia  outer protein M (YopM) to a human subject cutaneously, wherein administering prevents the psoriasis and wherein YopM does not enter the lymph node. 
     
     
         2 . The method according to  claim 1  wherein the psoriasis is selected from the group consisting of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and arthritis psoriasis. 
     
     
         3 . The method according to  claim 1  wherein the YopM is from a species selected from the group consisting of  Yersinia enterocolitica, Yersinia pseudotuberculosis  or  Yersinia pestis.    
     
     
         4 . The method according to  claim 1 , wherein the  Yersinia  outer protein M (YopM) is provided in a cream, lotion, gel or ointment. 
     
     
         5 . The method according to  claim 4 , wherein the cream is a semi-solid emulsion. 
     
     
         6 . The method according to  claim 5 , wherein the cream is an oil-in water or water-in oil cream. 
     
     
         7 . The method according to  claim 1 , wherein the composition further comprises one or more of carriers, excipients, or diluents. 
     
     
         8 . The method according to  claim 1 , wherein the composition further comprises one or more of cetearyl alcohol, paraffinum liquidum, glycerol, dimethicone, sodium cetearyl sulfate, phenoxyethanol, methylparaben, ethylparaben, propylparaben, or sodium hydroxide. 
     
     
         9 . The method according to  claim 1 , wherein the step of administering provides YopM in an amount in the range of 1 μg/cm 2  to 20 mg/cm 2  (YopM/cutaneous area). 
     
     
         10 . The method according to  claim 9 , wherein the amount is in the range of 1 μg/cm 2  to 20 μg/cm 2 . 
     
     
         11 . The method according to  claim 10 , wherein the amount is 2 μg/cm 2 . 
     
     
         12 . The method according to  claim 1 , wherein the step of administering is performed every 12 hours, or every 24 hours.